← Back to headlines
Gilead to Acquire Cancer Therapy Developer Arcellx for Up to $7.8 Billion
Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.
23 Feb, 12:52 — 23 Feb, 12:52
Sources
Showing 1 of 1 sources
